Skip to main content
    X

    X4 Pharmaceuticals Inc (XFOR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.09
    +0.26 (+9.19%)

    Market Cap: $288.98M

    Last updated: Nov 17, 2026 at 4:33 PM ET

    X4 Pharmaceuticals Inc (XFOR) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    X4 Pharmaceuticals (XFOR) has a market cap of $288.98M and an enterprise value of $180.19M. Its share count is up 192.39% from a year earlier. It kept -487.03% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 37.65% below the market cap, as cash exceeds debt.

    Market Cap$288.98M
    Enterprise Value$180.19M
    Latest price (Nov 17, 2026)$3.09

    Key Dates

    The next earnings report is expected on Mar 15, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 15, 2027 (expected)
    Last Earnings DateNov 4, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.14% in the quarter ended Sep 30, 2026 and grew 334.70% a year over 2 years.

    Shares Outstanding126.52M
    Shares Change (YoY)+192.39%
    Shares Change (QoQ)+0.14%
    Share Count Growth (2Y CAGR)+334.70%

    Valuation Ratios

    Sales and book value multiples are 23.6x and 2.8x. Its year-end P/S ranged from 0.9x to 190.3x from 2019 to 2025.

    P/S Ratio23.6x
    Forward P/S16.8x
    P/B Ratio2.8x
    P/TBV Ratio3.6x

    Valuation history and multiples

    Price Statistics

    The stock is down 15.57% over 52 weeks and trades 0.96% below its 50-day average.

    Beta (1Y)1.59
    52-Week Change-15.57%
    1-Month Change+12.36%
    3-Month Change-25.72%
    6-Month Change-15.11%
    5-Year Change-97.70%
    Total Return (1Y)-15.57%
    Total Return (3Y CAGR)-49.42%
    Total Return (5Y CAGR)-53.66%
    Return vs SPY (1Y)-25.73%
    Max Drawdown (1Y)-47.54%
    Max Drawdown (3Y)-96.78%
    Sharpe Ratio (1Y)-0.21
    Correlation with SPY (1Y)0.30
    50-Day Average$3.12
    200-Day Average$3.77
    52-Week Range$2.43 to $4.83
    RSI (14 Days)48.2
    Average Volume (20 Days)770.49K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 13.22x current liabilities, and total debt is 0.55x shareholder equity.

    Current Ratio13.22x
    Quick Ratio12.86x
    Debt / Equity0.55x
    Interest Coverage-9.19x

    Returns and Efficiency

    Return on invested capital is -36.93% over the last 12 months, against a 5-year average of -66.09%.

    Return on Equity (ROE)-57.98%
    Return on Assets (ROA)-34.73%
    Return on Invested Capital (ROIC)-36.93%
    Return on Capital Employed (ROCE)-36.77%
    ROA (5Y Average)-51.51%
    ROIC (5Y Average)-66.09%
    Asset Turnover0.08x
    Inventory Turnover0.56x
    Receivables Turnover9.40x
    Cash Conversion Cycle168 days

    Scores

    XFOR has an Altman Z-Score of -1.52, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.

    Altman Z-Score-1.52
    Altman Z ZoneDistress
    Piotroski F-Score4 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $16.53M over the last 12 months is down 51.34% from the 12 months before.

    Revenue$16.53M
    Revenue Growth (YoY)-51.34%
    Gross Profit$13.44M
    Operating Income-$80.39M
    Pretax Income-$80.52M
    Net Income-$80.52M
    EBITDA-$77.95M
    EBIT-$79.73M
    Reported EPS (TTM)-$0.67

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 59.91% of the $231.82M in total assets.

    Cash and Equivalents$185.80M
    Total Debt$77.01M
    Net Cash$108.79M
    Net Cash Per Share$0.86
    Working Capital$183.15M
    Shareholder Equity$138.88M
    Book Value Per Share$1.10
    Tangible Book Value$108.71M
    Tangible Book Per Share$0.86
    Total Assets$231.82M
    Total Liabilities$92.93M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$76.10M
    FCF Per Share-$1.00
    Depreciation and Amortization$1.77M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -486.22%.

    Gross Margin81.30%
    Operating Margin-486.22%
    Pretax Margin-487.00%
    Net Margin-487.03%
    EBITDA Margin-471.51%
    EBIT Margin-482.24%

    Growth

    Revenue Growth (5Y CAGR)+68.79%
    Book Value Per Share Growth (2Y CAGR)-53.26%
    Tangible Book Per Share Growth (2Y CAGR)-46.75%

    Revenue and profit by year

    Dividends and Yields

    XFOR does not pay a dividend.

    Buyback Yield-37.39%
    Shareholder Yield-37.39%

    Stock Splits

    The last split was a 1-for-30 reverse split on Apr 28, 2025.

    Last Split DateApr 28, 2025
    Split TypeReverse split
    Split Ratio1:30

    Peer Position

    Against 6 similar companies, XFOR has the 2nd highest P/S.

    P/S Ratio23.6x vs 5.5x median
    ROIC-36.93% vs -6.74% median
    Revenue Growth (Trailing 4 Quarters, YoY)-51.34% vs -85.57% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -42.42% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-42.42%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About XFOR

    What is XFOR's market cap?

    X4 Pharmaceuticals has a market cap of $288.98M. Its enterprise value, which adds debt and subtracts cash, is $180.19M.

    How many shares of XFOR are outstanding?

    X4 Pharmaceuticals has 126.52M shares outstanding. The count is up 192.39% from a year earlier.

    Does XFOR pay a dividend?

    No. X4 Pharmaceuticals does not pay a dividend.

    How much debt does XFOR have?

    X4 Pharmaceuticals has $77.01M of total debt and $185.80M of cash and equivalents, a net cash position of $108.79M.